JP2015535270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535270A5 JP2015535270A5 JP2015540120A JP2015540120A JP2015535270A5 JP 2015535270 A5 JP2015535270 A5 JP 2015535270A5 JP 2015540120 A JP2015540120 A JP 2015540120A JP 2015540120 A JP2015540120 A JP 2015540120A JP 2015535270 A5 JP2015535270 A5 JP 2015535270A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diseases
- agent
- convulsions
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190859.4 | 2012-10-31 | ||
| EP12190859 | 2012-10-31 | ||
| PCT/EP2013/072774 WO2014068035A1 (en) | 2012-10-31 | 2013-10-31 | Novel rock inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535270A JP2015535270A (ja) | 2015-12-10 |
| JP2015535270A5 true JP2015535270A5 (https=) | 2016-12-22 |
| JP6205425B2 JP6205425B2 (ja) | 2017-09-27 |
Family
ID=47148627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540120A Expired - Fee Related JP6205425B2 (ja) | 2012-10-31 | 2013-10-31 | 新規のｒｏｃｋ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9394286B2 (https=) |
| EP (1) | EP2914590B1 (https=) |
| JP (1) | JP6205425B2 (https=) |
| KR (1) | KR102242280B1 (https=) |
| CN (1) | CN104822676B (https=) |
| AU (1) | AU2013340854B2 (https=) |
| BR (1) | BR112015009504A2 (https=) |
| CA (1) | CA2922312C (https=) |
| DK (1) | DK2914590T3 (https=) |
| EA (1) | EA026629B1 (https=) |
| ES (1) | ES2617495T3 (https=) |
| IL (1) | IL238391A (https=) |
| IN (1) | IN2015DN04311A (https=) |
| MX (1) | MX362485B (https=) |
| NZ (1) | NZ708526A (https=) |
| PL (1) | PL2914590T3 (https=) |
| PT (1) | PT2914590T (https=) |
| SG (1) | SG11201503134WA (https=) |
| WO (1) | WO2014068035A1 (https=) |
| ZA (1) | ZA201503544B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US11202773B2 (en) * | 2015-04-20 | 2021-12-21 | University Of Houston System | Locally bioavailable drugs |
| WO2017114275A1 (zh) * | 2015-12-31 | 2017-07-06 | 成都先导药物开发有限公司 | 一种抑制rock的化合物及其制备方法与应用 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| EP4431596A4 (en) | 2021-11-11 | 2026-01-14 | The Doshisha | CRYOCONSERVATION PREPARATION FOR CORNIAL ENDOTHELIAL CELLS AND PROCESS FOR PRODUCING SAID CRYOCONSERVATION PREPARATION |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| US20090325959A1 (en) | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
| EP2317849A4 (en) | 2008-06-26 | 2011-11-02 | Inspire Pharmaceuticals Inc | PROCESS FOR THE TREATMENT OF LUNG DISEASES WITH RHO KINASE INHIBITOR COMPOUNDS |
| US20090325960A1 (en) | 2008-06-26 | 2009-12-31 | Fulcher Emilee H | Method for treating inflammatory diseases using rho kinase inhibitor compounds |
| US20100204210A1 (en) | 2008-12-04 | 2010-08-12 | Scott Sorensen | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
| CA2781390A1 (en) * | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| RU2013107007A (ru) * | 2010-07-19 | 2014-08-27 | Инспайр Фармасьютикалз, Инк. | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение |
| KR20130095263A (ko) * | 2010-07-27 | 2013-08-27 | 인스파이어 파마슈티컬스 인코퍼레이티드 | 전구약물 형태의 키나아제 저해제 화합물을 사용하여 안질환을 치료하는 방법 |
| GB201107223D0 (en) * | 2011-04-29 | 2011-06-15 | Amakem Nv | Novel rock inhibitors |
-
2013
- 2013-10-31 SG SG11201503134WA patent/SG11201503134WA/en unknown
- 2013-10-31 BR BR112015009504A patent/BR112015009504A2/pt not_active Application Discontinuation
- 2013-10-31 PL PL13786455T patent/PL2914590T3/pl unknown
- 2013-10-31 MX MX2015005459A patent/MX362485B/es active IP Right Grant
- 2013-10-31 NZ NZ708526A patent/NZ708526A/en not_active IP Right Cessation
- 2013-10-31 EP EP13786455.9A patent/EP2914590B1/en active Active
- 2013-10-31 DK DK13786455.9T patent/DK2914590T3/en active
- 2013-10-31 IN IN4311DEN2015 patent/IN2015DN04311A/en unknown
- 2013-10-31 KR KR1020157014431A patent/KR102242280B1/ko not_active Expired - Fee Related
- 2013-10-31 WO PCT/EP2013/072774 patent/WO2014068035A1/en not_active Ceased
- 2013-10-31 JP JP2015540120A patent/JP6205425B2/ja not_active Expired - Fee Related
- 2013-10-31 AU AU2013340854A patent/AU2013340854B2/en not_active Ceased
- 2013-10-31 PT PT137864559T patent/PT2914590T/pt unknown
- 2013-10-31 CN CN201380056608.XA patent/CN104822676B/zh not_active Expired - Fee Related
- 2013-10-31 EA EA201590847A patent/EA026629B1/ru unknown
- 2013-10-31 US US14/437,919 patent/US9394286B2/en not_active Expired - Fee Related
- 2013-10-31 ES ES13786455.9T patent/ES2617495T3/es active Active
- 2013-10-31 CA CA2922312A patent/CA2922312C/en active Active
-
2015
- 2015-04-20 IL IL238391A patent/IL238391A/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03544A patent/ZA201503544B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535270A5 (https=) | ||
| EA201591269A1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| SG11201911929XA (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| EP3718561A4 (en) | Therapy for inflammatory bowel disease | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| NZ741082A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| WO2009043522A3 (en) | Use of a peptide as a therapeutic agent | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| HUE059752T2 (hu) | A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek | |
| IL283469A (en) | Inhalable preparations for use in the treatment of lung diseases | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| EP3003343A4 (en) | BIOMIMETIC PEPTIDE AND BIODEGRADABLE OUTPUT PLATFORM FOR THE TREATMENT OF ANGIOGENESIS AND LYMPHANGIOGENESIS DEPENDENT ILLNESSES | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| EP3405159A4 (en) | TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASES THROUGH PHOTO COAGULATION | |
| HRP20191240T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
| JP2017522288A5 (https=) | ||
| TN2015000356A1 (en) | Bicyclic compounds | |
| JP2013523758A5 (https=) | ||
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| JP2016523943A5 (https=) | ||
| EP2928460A4 (en) | METHOD FOR PREVENTING AND TREATING FLAMMABLE SKIN DISEASES | |
| MX2017005103A (es) | Proceso de sintesis de hidroxi-triacilgliceroles y usos de los mismos para la prevencion y el tratamiento de enfermedades. |